GlassScriptPhysician profile
Kari D Sears
NPI 1548556111
$1,556.07
in general payments reported to CMS, 2019-2025
26 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $53.52 · 2023: $324 · 2024: $522 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $352.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $258.90 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $157.57 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $156.38 | 2023-2024 | Vraylar, Linzess, Viberzi |
| Abbott Laboratories | $72.23 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $63.58 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.50 | 2023-2024 | |
| Daiichi Sankyo INC. | $47.74 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $46.61 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Seqirus USA INC | $41.89 | 2019-2025 | Fluad, Flucelvax |
| Novartis Pharmaceuticals Corporation | $34.70 | 2019-2025 | |
| Dexcom, INC. | $31.21 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $24.42 | 2023 | Watchman Access System |
| Lilly USA, LLC | $22.59 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $21.43 | 2025 | Givlaari |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.02 | 2024 | Rejoyn |
| Insulet Corporation | $20.91 | 2025 | Omnipod |
| Biogen, INC. | $16.02 | 2025 | Zurzuvae |
| Amarin Pharma, INC. | $15.06 | 2020 | |
| Amgen INC. | $14.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.52 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.60 | 2023 | Qelbree |
| Depuy Synthes Sales INC. | $13.32 | 2023 | Orthovisc, Monovisc |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.69 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.58 | 2019 | |
| Sanofi Pasteur INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Sears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.